Nattokinase: Pros, Cons, and Longevity Evidence
Nattokinase is a fibrinolytic enzyme derived from natto, fermented soybeans made with Bacillus subtilis natto. Smaller studies report cardiovascular-marker signals, but the largest long-term randomized trial located for this report found no significant benefit on subclinical atherosclerosis progression, blood pressure, or laboratory measures in low-risk healthy adults.
Executive Summary
Potential benefits cluster around fibrinolysis, coagulation markers, and blood pressure in small studies. The core limitation is that the strongest long-term randomized trial found a null effect on carotid intima-media thickness, carotid arterial stiffness, blood pressure, and laboratory measures after a median 3 years of treatment. Direct evidence for human longevity extension is not established. Safety concerns center on bleeding risk, anticoagulant or antiplatelet interactions, surgery, bleeding disorders, and replacing prescribed anticoagulants.
Visual Analytics
Scores reflect confidence in the evidence behind each claim, not a recommendation to use nattokinase. Higher scores mean stronger, more direct human evidence; lower scores mean indirect, preliminary, or contradicted evidence.
72% confidence: controlled human crossover data, but only 12 healthy young men and surrogate markers.
58% confidence: small RCT signal, weakened by NAPS null BP result over longer follow-up.
28% confidence: the largest long-term RCT found no significant effect versus placebo.
12% confidence: no cited human lifespan or mortality trial supports a longevity claim.
Pros and Cons Table
Each row states what is supported, what is not yet proven, and the practical interpretation for health and longevity.
| Area | Potential Pro | Con or Limitation | Evidence Status | Confidence |
|---|---|---|---|---|
| Fibrinolysis | A double-blind crossover study in 12 healthy young men found that a single 2,000 FU dose increased D-dimer at 6 and 8 hours, increased FDP at 4 hours, reduced factor VIII activity at 4 and 6 hours, and increased antithrombin at 2 and 4 hours; all changes stayed within normal ranges. | This was acute marker data in a small homogeneous group. It did not prove fewer heart attacks, strokes, clots, or deaths. | Promising markers | 72% Controlled design and direct lab markers, but small sample and surrogate outcomes. |
| Blood pressure | A North American randomized, double-blind, placebo-controlled trial enrolled 79 adults with elevated BP; 74 completed. A 100 mg daily product standardized to at least 2,000 FU for 8 weeks was associated with lower diastolic BP versus placebo, with the strongest signal in men. | The systolic BP change did not reach between-group statistical significance in that study, and the trial was small. It is not a substitute for diagnosed hypertension care. | Limited RCT signal | 58% Some RCT support, but limited size and contradicted by NAPS null BP findings. |
| Atherosclerosis | A 2018 review summarized a 2017 clinical study reporting reduced carotid plaque size and common carotid intima-media thickness after 26 weeks of 6,500 FU/day nattokinase in patients with plaques. | The larger NAPS randomized trial enrolled 265 adults without clinical CVD and found no significant difference versus placebo in annualized carotid intima-media thickness or carotid arterial stiffness after a median 3 years of 2,000 FU/day. | Long-term null result | 28% Confidence in benefit is low because the strongest long-term trial was null. |
| Clinical outcomes | The biological rationale is plausible because thrombosis, blood pressure, and vascular aging are longevity-relevant pathways. | No cited trial established reductions in heart attack, stroke, dementia, all-cause mortality, or lifespan extension from nattokinase supplementation. | Not demonstrated | 18% Biological plausibility exists, but clinical outcomes are unproven. |
| Longevity | Natto intake has been associated with lower cardiovascular mortality in observational Japanese diet research, and natto extract extended lifespan in C. elegans in a preclinical study cited by reviews. | These findings do not prove nattokinase supplements extend human lifespan. Whole-food natto contains many compounds besides nattokinase, and model-organism findings do not translate directly to humans. | Not proven | 12% Evidence is indirect and not supplement-specific in humans. |
| Safety | Small human studies and toxicology work reviewed in PMC sources reported good tolerability under study conditions; one review notes 10 mg/kg/day for 28 days was well tolerated in healthy volunteers. | Drug interactions and contraindications are not fully characterized. A review cites a cerebellar hemorrhage case with nattokinase plus aspirin and a mechanical-valve thrombosis case after substituting nattokinase for warfarin. | Medication risk | 80% High confidence that caution is warranted because case reports and clotting mechanism align. |
| Vitamin K context | Some studied nattokinase extracts remove vitamin K2, which matters because natto itself is vitamin-K rich. | NIH ODS states vitamin K can seriously interact with warfarin; people on warfarin need consistent vitamin K intake and medical guidance. | Warfarin caution | 92% Strong NIH ODS support for warfarin/vitamin K caution; product vitamin K2 content can vary. |
Longevity Read
The longevity case is indirect and currently weak. Cardiovascular risk reduction can be longevity-relevant in general, but nattokinase has not been validated as a human longevity intervention. The strongest honest statement is: nattokinase has plausible cardiovascular-marker relevance, but human lifespan, all-cause mortality, dementia prevention, and cardiovascular-event reduction remain unproven for supplements. The largest long-term RCT found null effects on subclinical atherosclerosis progression and measured lab outcomes in low-risk healthy adults.
Verdict
Nattokinase is scientifically interesting, but current evidence is not strong enough to call it a proven healthspan, longevity, cardiovascular-prevention, or cognitive-protection supplement. It should not replace prescribed antiplatelet, anticoagulant, antihypertensive, lipid-lowering, or cardiovascular therapies.
References and Validation Notes
Facts in this report were checked against the following sources. No unsourced dosing recommendation is made.
- Jensen et al., 2016 - randomized, double-blind, placebo-controlled North American BP/vWF trial; 79 enrolled, 74 completed, 100 mg/2,000 FU daily for 8 weeks.
- Kurosawa et al., 2015 - double-blind, placebo-controlled crossover study of a single 2,000 FU dose in 12 healthy young men with fibrinolysis/coagulation-marker changes.
- Chen et al., 2018 - cardiovascular review summarizing clinical studies, advantages, remaining issues, and interaction concerns.
- Weng et al., 2017 - review of nattokinase mechanisms, safety assessment, production, and limitations.
- Hodis et al., 2021 - Nattokinase Atherothrombotic Prevention Study publication; 265 randomized adults, median age 65.3 years, median 3 years, null effect on CIMT, carotid arterial stiffness, BP, and laboratory determinations.
- ClinicalTrials.gov NCT02080520 - Nattokinase Atherothrombotic Prevention Study trial record; completed, 265 actual enrollment, 2,000 FU/day versus placebo, 3-year endpoints.
- NIH Office of Dietary Supplements Vitamin K fact sheet - vitamin K clotting role and serious warfarin interaction context.
- Memorial Sloan Kettering About Herbs: Nattokinase - supplement safety context and medical-advice disclaimer.